MWNA
SYRE icon

Marshall Wace North America’s Spyre Therapeutics SYRE Stock Holding History

Marshall Wace North America’s Portfolio SYRE Stock Details SYRE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-268
Closed -$51K – 1585
2019
Q4 		$51K Buy
+268
New +$52.6K ﹤0.01% 1151
2019
Q2 		– Sell
-892
Closed -$179K – 1589
2019
Q1 		$179K Buy
+892
New +$186K ﹤0.01% 1011

Other funds holding SYRE

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
ACM
Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Marshall Wace North America's SYRE Position: Q1 2020 in Review

Marshall Wace North America sold out of Spyre Therapeutics (SYRE) in Q1 2020, closing a stake of 268 shares — an estimated $51K sold.

Marshall Wace North America first reported a position in SYRE in Q1 2019 and held it in 2 quarters. The position peaked at $179K in Q1 2019. 70 funds tracked by Wall St. Rank hold SYRE as of Q1 2020.

  • Marshall Wace North America reported no remaining Spyre Therapeutics position as of Q1 2020 after selling out during the quarter.
  • Marshall Wace North America sold 268 Spyre Therapeutics shares in Q1 2020, an estimated $51K.
  • Marshall Wace North America first reported a position in Spyre Therapeutics in Q1 2019 and held it in 2 quarters.
  • Marshall Wace North America's Spyre Therapeutics position peaked at $179K in Q1 2019.
  • 70 funds tracked by Wall St. Rank held Spyre Therapeutics as of Q1 2020.

Based on Marshall Wace North America's 13F filing for Q1 2020, filed 15 May 2020.